Written by Nicole Safran presented by Chronic Migraine Awareness, Inc.
When I heard a new migraine abortive drug class, gepants, was approved by the FDA, I was ecstatic. An abortive is a medication used to stop a migraine attack after one has begun. Like many, I’ve tried the available abortive medications and have not had the greatest success. I still live life with chronic, intractable migraine that interfere with my daily life.
On December 23, 2019, the FDA approved ubrogepant, a calcitonin gene-related peptide (CGRP) for for the acute treatment of migraine in adults with and without aura. Two trials conducted were ACHIEVE-1 and ACHIEVE-2. Both found pain relief in 2 hours and significant improvement compared to placebo (the sugar pill). Further, there were NO side effects reported. Unlike triptans, there are no cardiovascular risk factors. One of the main reasons I’ve stopped taking medications is due to troublesome side effects.
There have been so many new therapies coming to the market in the past few years, with new ones expected, it’s such an exciting time for migraine patients. It leaves me overfilled with hope for the future – hope for reduced pain, fewer attacks, and painless days.